The anti-inflammatory potential of cefazolin as common gamma chain cytokine inhibitor.
Ontology highlight
ABSTRACT: A continuing quest for specific inhibitors of proinflammatory cytokines brings promise for effective therapies designed for inflammatory and autoimmune disorders. Cefazolin, a safe, first-generation cephalosporin antibiotic, has been recently shown to specifically interact with interleukin 15 (IL-15) receptor subunit ? (IL-15R?) and to inhibit IL-15-dependent TNF-? and IL-17 synthesis. The aim of this study was to elucidate cefazolin activity against IL-2, IL-4, IL-15 and IL-21, i.e. four cytokines sharing the common cytokine receptor ? chain (?c). In silico, molecular docking unveiled two potential cefazolin binding sites within the IL-2/IL-15R? subunit and two within the ?c subunit. In vitro, cefazolin decreased proliferation of PBMC (peripheral blood mononuclear cells) following IL-2, IL-4 and IL-15 stimulation, reduced production of IFN-?, IL-17 and TNF-? in IL-2- and IL-15-treated PBMC and in IL-15 stimulated natural killer (NK) cells, attenuated IL-4-dependent expression of CD11c in monocyte-derived dendritic cells and suppressed phosphorylation of JAK3 in response to IL-2 and IL-15 in PBMC, to IL-4 in TF-1 (erythroleukemic cell line) and to IL-21 in NK-92 (NK cell line). The results of the study suggest that cefazolin may exert inhibitory activity against all of the ?c receptor-dependent cytokines, i.e. IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21.
SUBMITTER: Zyzynska-Granica B
PROVIDER: S-EPMC7031511 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA